PROCF (Sofgen Pharma) NonCurrent Deferred Revenue: $0.0 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PROCF Sofgen Pharma SA PROCF
24 GF Score
Price $0.00
View Full Analysis

What is Sofgen Pharma NonCurrent Deferred Revenue?

Sofgen Pharma PROCF 24 NonCurrent Deferred Revenue is $0.0 Mil as of Dec. 2024. GuruFocus rates PROCF with a GF Score™ of 24/100.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Sofgen Pharma's non-current deferred revenue for the quarter that ended in Dec. 2024 was $0.0 Mil.

Sofgen Pharma NonCurrent Deferred Revenue Related Terms

Sofgen Pharma NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Sofgen Pharma's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sofgen Pharma NonCurrent Deferred Revenue Chart

Sofgen Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
NonCurrent Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Sofgen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Dec24
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PROCF
24GF Score
Sofgen Pharma SA PROCF
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0.0 Mil mean?
Sofgen Pharma (PROCF) has a NonCurrent Deferred Revenue of $0.0 Mil as of Dec. 2024. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Sofgen Pharma and its competitors.
Is Sofgen Pharma's NonCurrent Deferred Revenue too high?
Sofgen Pharma's current NonCurrent Deferred Revenue is $0.0 Mil. Overall, Sofgen Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sofgen Pharma's NonCurrent Deferred Revenue compare to BKUH and ORGO?
Sofgen Pharma's NonCurrent Deferred Revenue of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Drug Manufacturers company?
A good NonCurrent Deferred Revenue depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Sofgen Pharma and its competitors. Sofgen Pharma's current NonCurrent Deferred Revenue is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sofgen Pharma stock overvalued right now?
Sofgen Pharma (PROCF) has a current NonCurrent Deferred Revenue of $0.0 Mil. The current NonCurrent Deferred Revenue is $0.0 Mil. Sofgen Pharma's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Sofgen Pharma (PROCF), the current NonCurrent Deferred Revenue is $0.0 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sofgen Pharma Business Description

Address 9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is an integrated healthcare and pharmaceutical company that develops and manufactures pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The company's segment includes NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. It generates maximum revenue from the NextGel segment. It has geographic presence in Bolivia, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, and the United States.
24GF Score

Get the complete analysis for PROCF

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price